Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% ...

Why future-ready pharma companies must embrace AI-driven, real-time decision-making. Lightship’s Approach to Accessible, Representative, and Impactful Clinical Trials ...

Over the past decade, artificial intelligence (AI) and automation have reshaped clinical research. From identifying drug ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, shares real-world examples of AI transforming clinical ...

As biotech innovation accelerates, the clinical research workforce is rapidly eroding—threatening the future of drug development. From workforce burnout to training program cuts and talent pipeline ...

In this video interview, Kyle McAllister, co-founder, CEO, Trially, explains how AI is stepping in to fill staffing gaps in ...

Bemarituzumab Shows Survival Benefit: The Phase III FORTITUDE-101 trial met its primary endpoint, with bemarituzumab plus chemotherapy significantly improving overall survival in FGFR2b-positive, HER2 ...

How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating evidence in broader, more representative patient populations.

How clinical operations teams can close the gap between controlled trial results and real-world adoption by generating ...